Renal dosimetry in 177 Lu-PSMA-617: What predicts kidney dose? (EANM 2026) - Sep 29, 2026 - Abstract #EP-1033; "The kidney absorbed dose in 177Lu-PSMA-617 therapy showed no consistent association with pre-therapeutic MAG3 parameters or standard renal function markers. Further inclusion of patients is needed to clarify whether the observed variability and missing correlation of Dblood in C3 reflects true biological effects or is due to the limited sample size."
Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
N. Zindler; S. Schumann; P. E. Hartrampf; N. Hasenauer; I. Strobel; M. Lassmann; U. Eberlein
|